February 25, 2021
Business News

Harris Williams Advises Altasciences on its Pending Sale to Novo Holdings A/S


RICHMOND, Va.–()–Harris Williams, a global investment bank specializing in M&A advisory services, announces it is the lead advisor to Altasciences, a portfolio company of Audax Private Equity, on its pending sale to Novo Holdings A/S (Novo Holdings). Founded in 1992, Altasciences is a fully integrated, early drug development services platform, providing the pharma and biotech industries with a trusted partner for drug development, from preclinical safety testing through to clinical proof-of-concept studies. The transaction is being led by Paul Hepper, Geoffrey Smith, Tyler Bradshaw, Miles Annin and Bill Whitaker of the Harris Williams Healthcare & Life Sciences (HCLS) Group and Daniel Wang, a managing director…



Click here to view the original article.

Related Posts

You might also like ...

AON Splash Image
Wellington Management Expands Private Investing Capabilities with New Climate-Focused Senior Investors
Genus plc Reports Interim First Half 2021 Fiscal Year Results
L&T Technology Services Selected by Airbus for Skywise Partner Programme